Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (UNAUDITED)

v3.20.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Stockholders Deficit TransBiotec Inc [Member]
Preferred Stock [Member]
Accumulated Deficit [Member]
Noncontrolling Interest [Member]
Balance, shares at Dec. 31, 2018   116,751,078     1,388,575    
Balance, amount at Dec. 31, 2018 $ (3,423,431) $ 1,172 $ 14,887,804 $ (3,373,146) $ 14 $ (18,262,136) $ (50,285)
Common stock issued for cash, shares   35,454,547        
Common stock issued for cash, amount 39,000 $ 350 38,650 39,000
Paid-in capital - fair value of stock warrants granted 22,665 22,665 22,665
Paid-in capital - gain on related party debt conversion 8,113 8,113 8,113
Net loss for the period (139,056) (138,289) (138,289) (767)
Balance, shares at Mar. 31, 2019   152,205,625     1,388,575    
Balance, amount at Mar. 31, 2019 (3,492,709) $ 1,522 14,957,232 (3,441,657) $ 14 (18,400,425) (51,052)
Balance, shares at Dec. 31, 2019   214,626,540        
Balance, amount at Dec. 31, 2019 (3,593,121) $ 2,146 15,969,311 (3,539,711) (19,511,168) (53,410)
Common stock issued to settle accounts payable, amount 54,682 13 54,669 54,682      
Net loss for the period (449,874) (450,023) (450,023) 149
Common stock issued for compensation, shares   20,000        
Common stock issued for compensation, amount 20,800 20,800 20,800
Common stock issued due to stock warrants exercise, shares   15,103,261        
Common stock issued due to stock warrants exercise, amount $ 65,875 $ 151 $ 65,724 $ 65,875
Common stock issued to settle related party payables, shares 7,147,001
Common stock issued to settle related party payables, amount $ 306,606 $ 71 $ 306,535 $ 306,606    
Common stock issued to settle accounts payable, shares 1,274,636
Common stock issued to settle related party debt, shares   21,577,069        
Common stock issued to settle related party debt, amount $ 851,975 $ 215 $ 851,760 $ 851,975
Common stock issued to settle non-related party debt, shares   2,343,110        
Common stock issued to settle non-related party debt, amount 165,182 $ 23 165,159 165,182
Paid-in capital - fair value of related party stock options vested 39,450 39,450 39,450
Paid-in capital - gain on related party payables conversion 408,094 408,094 408,094
Paid-in capital - gain on related party debt conversion 99,647 99,647 99,647
Paid-in capital - loss on debt extinguishment 155,357 155,357 155,357
Paid-in capital - beneficial conversion feature 174 174 174
Balance, shares at Mar. 31, 2020   262,091,617        
Balance, amount at Mar. 31, 2020 $ (1,875,153) $ 2,619 $ 18,136,680 $ (1,821,892) $ (19,961,191) $ (53,261)